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359high risk, so the patient was referred for percutaneous
therapy.
A 30-mm Amplatzer Multi-Fenestrated “Cribiform”
Septal Occluder (AGA Medical, Plymouth, Minnesota)
was delivered across the aortic valve via a percutaneously
placed 9-F TorqVue catheter. With transesophageal echo-
cardiography guidance, the device was positioned across the
valve, resulting in no residual AI, mitral obstruction, or
coronary occlusion (Online Video 1). The LVAD flow rates
immediately decreased, and transthoracic echocardiography
performed 1 week later demonstrated no AI (Fig. 1, Online
Video 2).
One concerning complication of LVAD support is the
development of hemodynamically significant AI, with one
study reporting its presence in 51% of patients at 18 months
(1). The development of late AI is associated with increased
mortality and has been associated with functional closure of
the aortic valve due to the newly implanted LVAD in the
first month after implantation (1, 2). The mechanism of late
AI is uncertain, but aortic root dilation and myxoid degen-
eration of the aortic valve are thought to be contributing
factors (2).
Transcatheter treatment of AI in a neonate with hyp-
oplastic left heart syndrome was accomplished with a 4-mm
Amplatzer Septal Occluder (3). Grohmann et al. (4) re-
ported treatment of LVAD-associated AI with transcathe-
ter placement of an Amplatzer ventricular septal defectdevice via surgical cut-down of the left subclavian artery and
placement of a 12-F sheath.
Widespread use of LVADs might result in an increasing
incidence of LVAD-associated AI. Surgery requires an
additional thoracotomy in patients who are already at high
operative risk. This case describes a previously unreported
percutaneous, transfemoral technique to successfully treat
AI and improve LVAD function.
Reprint requests and correspondence: Dr. Atman P. Shah, University
of Chicago Medical Center, 5841 South Maryland Avenue, MC 6080,
Chicago, Illinois 60637. E-mail: ashah5@uchicago.edu.
REFERENCES
1. Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Kolias
TJ. The development of aortic insufficiency in left ventricular assist
device-supported patients. Circ Heart Fail 2010;3:668–74.
2. Toda K, Fujita T, Domae K, Shimahara Y, Kobayashi J, Nakatani T.
Late aortic insufficiency related to poor prognosis during left ventricular
assist device support. Ann Thorac Surg 2011;92:929–3.
3. Riede FT, Kostelka M, Dahnert I. Transcatheter aortic valve closure to
treat severe aortic regurgitation in a patient failing stage 1 palliation for
hypoplastic left heart syndrome. Cath Cardiol Int 2009;74:913–5.
4. Grohmann J, Blanke P, Benk C, Schlensak C. Trans-catheter closure of
the native aortic valve with an Amplatzer occluder to treat progressive
aortic regurgitation after implantation of a left-ventricular assist device.
Eur J Cardiothorac Surg 2011;39:e181–3.
APPENDIXFor accompanying videos, please see the online version of this article.
